Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
J Gerontol A Biol Sci Med Sci ; 76(9): 1542-1550, 2021 08 13.
Article in English | MEDLINE | ID: mdl-33903897

ABSTRACT

The genitourinary syndrome of menopause (GSM) describes signs and symptoms resulting from effects of estrogen deficiency on the female genitourinary tract, including the vagina, labia, urethra, and bladder. Signs/symptoms associated with GSM may occur during any reproductive stage from multiple etiologies but are most common during menopause due to low estrogen. Vaginal microbiota, particularly Lactobacillus spp., are beneficial to the female genital tract; however, their abundance declines during menopause. We aimed to longitudinally assess vaginal microbiota characterized by 16S rRNA gene amplicon sequencing and GSM-associated endpoints across reproductive stages. In a 2-year cohort study of 750 women aged 35-60 years at enrollment and 2 111 semiannual person-visits, low-Lactobacillus vaginal microbiota communities were observed at 21.2% (169/798), 22.9% (137/597), and 49.7% (356/716) of person-visits among pre-, peri-, and postmenopausal women, respectively (p < .001). Compared to communities that have high Gardnerella vaginalis relative abundance and diverse anaerobes, the following communities were associated with a lower covariate-adjusted odds of vaginal atrophy: L crispatus-dominated communities among postmenopausal women (odds ratio [OR] = 0.25; 95% confidence interval [CI]: 0.08, 0.81), L gasseri/L jensenii (OR = 0.21; 95% CI: 0.05, 0.94) and L iners (OR = 0.21; 95% CI: 0.05, 0.85) among perimenopausal women, and L iners-dominated communities (OR = 0.18; 95% CI: 0.04, 0.76) among premenopausal women. Postmenopausal women with L gasseri/L jensenii-dominated communities had the lowest odds of vaginal dryness (OR = 0.36; 95% CI: 0.12, 1.06) and low libido (OR = 0.28; 95% CI: 0.10, 0.74). Findings for urinary incontinence were inconsistent. Associations of vaginal microbiota with GSM signs/symptoms are most evident after menopause, suggesting an avenue for treatment and prevention.


Subject(s)
Female Urogenital Diseases/microbiology , Gardnerella vaginalis/isolation & purification , Lactobacillus/isolation & purification , Menopause , Vagina/microbiology , Adult , Atrophy/microbiology , Dyspareunia/microbiology , Female , Humans , Microbiota , Middle Aged , Syndrome , Vaginal Diseases/microbiology , Vulvar Diseases/microbiology
2.
Sci Rep ; 11(1): 4143, 2021 02 18.
Article in English | MEDLINE | ID: mdl-33603125

ABSTRACT

Based on the antibody typing classification, Helicobacter pylori infection can be divided into type I H. pylori infection and type II H. pylori infection. To observe the effects of different H. pylori infection types on the distribution of histopathological characteristics and the levels of three items of serum gastric function (PG I, PG II, G-17). 1175 cases from October 2018 to February 2020 were collected with ratio 1:2. All patients were performed with 14C-Urea breath test (14C-UBT), H. pylori antibody typing classification, three items of serum gastric function detection, painless gastroscopy, pathological examination, etc. According to H. pylori antibody typing classification, patients were divided into three groups: type I H. pylori infection group, type II H. pylori infection group and control group. Significant difference existed among type I H. pylori infection group, type II H. pylori infection group and control group in inflammation and activity (χ2 = 165.43, 354.88, P all < 0.01). The proportion of three groups in OLGA staging had statistic difference (χ2 = 67.99, P all < 0.01); Compared with type II H. pylori infection group and control group, the level of pepsinogen I, pepsinogen II, gastrin17 in type I H. pylori infection group increased, and PG I/PG II ratio (PG I/PG II ratio, PGR) decreased, which was statistically significant (χ2 = 35.08, 166.24, 134.21, 141.19; P all < 0.01). Type I H. pylori infection worsened the severity of gastric mucosal inflammation and activity. H. pylori infection was prone to induce atrophy of gastric mucosa, while type I H. pylori infection played a key role in promoting the progress of atrophic gastritis and affected the level of serum gastric function. The study indicated that the eradication of H. pylori should be treated individually.


Subject(s)
Gastritis, Atrophic/microbiology , Gastritis, Atrophic/pathology , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Helicobacter pylori/pathogenicity , Acceleration , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/metabolism , Atrophy/metabolism , Atrophy/microbiology , Atrophy/pathology , Breath Tests/methods , Female , Gastric Mucosa/metabolism , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Gastritis, Atrophic/metabolism , Gastroscopy/methods , Helicobacter Infections/metabolism , Humans , Male , Middle Aged , Pepsinogen A/metabolism , Pepsinogen C/metabolism , Retrospective Studies , Stomach Neoplasms/metabolism , Stomach Neoplasms/microbiology , Stomach Neoplasms/pathology
3.
PLoS Pathog ; 16(12): e1008686, 2020 12.
Article in English | MEDLINE | ID: mdl-33370399

ABSTRACT

Helicobacter pylori chronically infects the stomach of approximately half of the world's population. Manifestation of clinical diseases associated with H. pylori infection, including cancer, is driven by strain properties and host responses; and as chronic infection persists, both are subject to change. Previous studies have documented frequent and extensive within-host bacterial genetic variation. To define how within-host diversity contributes to phenotypes related to H. pylori pathogenesis, this project leverages a collection of 39 clinical isolates acquired prospectively from a single subject at two time points and from multiple gastric sites. During the six years separating collection of these isolates, this individual, initially harboring a duodenal ulcer, progressed to gastric atrophy and concomitant loss of acid secretion. Whole genome sequence analysis identified 1,767 unique single nucleotide polymorphisms (SNPs) across isolates and a nucleotide substitution rate of 1.3x10-4 substitutions/site/year. Gene ontology analysis identified cell envelope genes among the genes with excess accumulation of nonsynonymous SNPs (nSNPs). A maximum likelihood tree based on genetic similarity clusters isolates from each time point separately. Within time points, there is segregation of subgroups with phenotypic differences in bacterial morphology, ability to induce inflammatory cytokines, and mouse colonization. Higher inflammatory cytokine induction in recent isolates maps to shared polymorphisms in the Cag PAI protein, CagY, while rod morphology in a subgroup of recent isolates mapped to eight mutations in three distinct helical cell shape determining (csd) genes. The presence of subgroups with unique genetic and phenotypic properties suggest complex selective forces and multiple niches within the stomach during chronic infection.


Subject(s)
Duodenal Ulcer/microbiology , Helicobacter Infections/complications , Helicobacter Infections/genetics , Helicobacter pylori/genetics , Stomach Diseases/microbiology , Animals , Atrophy/microbiology , Chronic Disease , Gastric Acid , Humans , Male , Mice , Mice, Inbred C57BL , Middle Aged , Phenotype , Polymorphism, Single Nucleotide , Stomach Diseases/pathology
5.
PLoS One ; 15(9): e0237515, 2020.
Article in English | MEDLINE | ID: mdl-32898138

ABSTRACT

BACKGROUND: Regional variations in gastric cancer incidence are not explained by prevalence of Helicobacter pylori, the main cause of the disease, with several areas presenting high H. pylori prevalence but low gastric cancer incidence. The IARC worldwide H. pylori prevalence surveys (ENIGMA) aim at systematically describing age and sex-specific prevalence of H. pylori infection around the world and generating hypotheses to explain regional variations in gastric cancer risk. METHODS: We selected age- and sex-stratified population samples in two areas with different gastric cancer incidence and mortality in Chile: Antofagasta (lower rate) and Valdivia (higher rate). Participants were 1-69 years old and provided interviews and blood for anti-H. pylori antibodies (IgG, VacA, CagA, others) and atrophy biomarkers (pepsinogens). RESULTS: H. pylori seroprevalence (Age-standardized to world population) and antibodies against CagA and VacA were similar in both sites. H. pylori seroprevalence was 20% among children <10 years old, 40% among 10-19 year olds, 60% in the 20-29 year olds and close to or above 80% in those 30+ years. The comparison of the prevalence of known and potential H. pylori cofactors in gastric carcinogenesis between the high and the low risk area showed that consumption of chili products was significantly higher in Valdivia and daily non-green vegetable consumption was more common in Antofagasta. Pepsinogen levels suggestive of gastric atrophy were significantly more common and occurred at earlier ages in Valdivia, the higher risk area. In a multivariate model combining both study sites, age, chili consumption and CagA were the main risk factors for gastric atrophy. CONCLUSIONS: The prevalence of H. pylori infection and its virulence factors was similar in the high and the low risk area, but atrophy was more common and occurred at younger ages in the higher risk area. Dietary factors could partly explain higher rates of atrophy and gastric cancer in Valdivia. IMPACT: The ENIGMA study in Chile contributes to better understanding regional variations in gastric cancer incidence and provides essential information for public health interventions.


Subject(s)
Helicobacter Infections/complications , Helicobacter pylori/isolation & purification , Stomach Neoplasms/etiology , Stomach/pathology , Adolescent , Adult , Aged , Atrophy/etiology , Atrophy/microbiology , Atrophy/pathology , Child , Child, Preschool , Chile/epidemiology , Female , Helicobacter Infections/epidemiology , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Humans , Infant , Male , Middle Aged , Prevalence , Risk Factors , Stomach/microbiology , Stomach Neoplasms/microbiology , Stomach Neoplasms/pathology , Young Adult
6.
Arq Gastroenterol ; 56(4): 419-424, 2019.
Article in English | MEDLINE | ID: mdl-31800739

ABSTRACT

BACKGROUND: Helicobacter pylori infection is the most important risk factor for gastric atrophy and intestinal metaplasia, both considered gastric cancer precursor lesions. Therefore, the investigation of the occurrence of H. pylori infection, precursor lesions and associated factors guides the adoption of specific strategies for the control this type of cancer. OBJECTIVE: To evaluate the prevalence of H. pylori infection in patients undergoing upper digestive endoscopy, as well as the prevalence of intestinal metaplasia, atrophy and chronic inflammation and their association with H. pylori infection. METHODS: A retrospective study was performed based on reports of gastric endoscopic biopsies performed in a private laboratory affiliated to the Brazilian Public Health System (SUS). Patients were evaluated for age, gender and type of health service. The samples were evaluated for the presence of H. pylori, and also of chronic inflammation, intestinal metaplasia and glandular atrophy. RESULTS: Of a total of 4,604 patients (mean age 51±16.6), 63.9% were female and 63.1% coming from private health care service. The prevalence of H. pylori infection was 31.7% (n=1,459), and the percentage of infection was significantly higher in patients from public health service (42.0%) in relation to patients from private health service (25.6%). Among H. pylori (+) patients, a higher percentage of intestinal metaplasia (17.7% vs 13.3%) and glandular atrophy (17.6% vs 6.9%) were observed when compared to those H. pylori (-) (P<0.01). From the patients H. pylori (+) with at least one type of precursor lesion (n=418), 161 (38.5%) had metaplasia and chronic inflammation, 160 (38.3%) had atrophy and chronic inflammation and finally 97 (23.2%) presented metaplasia, atrophy and chronic inflammation simultaneously. CONCLUSION: The present study reinforces the association of H. pylori infection with gastric cancer precursor lesions in a Brazilian population, emphasizing the importance of infection prevention measures, as well as the treatment of infected patients, especially in regions with lower socioeconomic levels that show a higher prevalence of infection by H. pylori.


Subject(s)
Helicobacter Infections/pathology , Helicobacter pylori , Stomach Neoplasms/microbiology , Adult , Aged , Atrophy/microbiology , Biopsy , Chronic Disease , Female , Gastroscopy , Humans , Male , Metaplasia/microbiology , Middle Aged , Precancerous Conditions/microbiology , Prevalence , Retrospective Studies , Risk Factors , Stomach Neoplasms/pathology
7.
Arq. gastroenterol ; 56(4): 419-424, Oct.-Dec. 2019. tab, graf
Article in English | LILACS | ID: biblio-1055178

ABSTRACT

ABSTRACT BACKGROUND: Helicobacter pylori infection is the most important risk factor for gastric atrophy and intestinal metaplasia, both considered gastric cancer precursor lesions. Therefore, the investigation of the occurrence of H. pylori infection, precursor lesions and associated factors guides the adoption of specific strategies for the control this type of cancer. OBJECTIVE: To evaluate the prevalence of H. pylori infection in patients undergoing upper digestive endoscopy, as well as the prevalence of intestinal metaplasia, atrophy and chronic inflammation and their association with H. pylori infection. METHODS: A retrospective study was performed based on reports of gastric endoscopic biopsies performed in a private laboratory affiliated to the Brazilian Public Health System (SUS). Patients were evaluated for age, gender and type of health service. The samples were evaluated for the presence of H. pylori, and also of chronic inflammation, intestinal metaplasia and glandular atrophy. RESULTS: Of a total of 4,604 patients (mean age 51±16.6), 63.9% were female and 63.1% coming from private health care service. The prevalence of H. pylori infection was 31.7% (n=1,459), and the percentage of infection was significantly higher in patients from public health service (42.0%) in relation to patients from private health service (25.6%). Among H. pylori (+) patients, a higher percentage of intestinal metaplasia (17.7% vs 13.3%) and glandular atrophy (17.6% vs 6.9%) were observed when compared to those H. pylori (-) (P<0.01). From the patients H. pylori (+) with at least one type of precursor lesion (n=418), 161 (38.5%) had metaplasia and chronic inflammation, 160 (38.3%) had atrophy and chronic inflammation and finally 97 (23.2%) presented metaplasia, atrophy and chronic inflammation simultaneously. CONCLUSION: The present study reinforces the association of H. pylori infection with gastric cancer precursor lesions in a Brazilian population, emphasizing the importance of infection prevention measures, as well as the treatment of infected patients, especially in regions with lower socioeconomic levels that show a higher prevalence of infection by H. pylori.


RESUMO CONTEXTO: A infecção por Helicobacter pylori é o fator de risco mais importante para atrofia gástrica e metaplasia intestinal, ambas consideradas lesões precursoras do câncer gástrico. Portanto, a investigação da ocorrência de infecção por H. pylori, das lesões precursoras e dos fatores associados orienta a adoção de estratégias específicas para o controle deste tipo de câncer. OBJETIVO: Avaliar a prevalência de infecção por H. pylori em pacientes submetidos à endoscopia digestiva alta, bem como a prevalência de metaplasia intestinal, atrofia e inflamação crônica e a associação destas com a infecção por H. pylori. MÉTODOS: Foi realizado um estudo retrospectivo com base em laudos de biópsias endoscópicas gástricas realizadas em laboratório privado afiliado ao Sistema Único de Saúde (SUS). Os pacientes foram avaliados quanto à idade, sexo e tipo de serviço de saúde. As amostras foram avaliadas quanto à presença de H. pylori e também de inflamação crônica, metaplasia intestinal e atrofia glandular. RESULTADOS: Do total de 4.604 pacientes (idade média de 51±16,6), 63,9% eram do sexo feminino e 63,1% provenientes de serviços de saúde privado. A prevalência de infecção por H. pylori foi de 31,7% (n=1.459) e o percentual de infecção foi significativamente maior nos pacientes do serviço público de saúde (42,0%) em relação aos pacientes do serviço privado de saúde (25,6%). Entre os pacientes com H. pylori (+), foi observado maior percentual de metaplasia intestinal (17,7% vs 13,3%) e atrofia glandular (17,6% vs 6,9%) quando comparados aos H. pylori (-) (P<0,01). Dos pacientes H. pylori (+) com pelo menos um tipo de lesão precursora (n=418), 161 (38,5%) apresentaram metaplasia e inflamação crônica, 160 (38,3%) apresentaram atrofia e inflamação crônica e, finalmente, 97 (23,2%) apresentaram metaplasia, atrofia e inflamação crônica simultaneamente. CONCLUSÃO: O presente estudo reforça a associação da infecção por H. pylori com lesões precursoras de câncer gástrico em uma população brasileira, enfatizando a importância de medidas de prevenção de infecção, bem como o tratamento de pacientes infectados, principalmente em regiões com níveis socioeconômicos mais baixos que apresentam maior prevalência de infecção por H. pylori.


Subject(s)
Humans , Male , Female , Adult , Aged , Stomach Neoplasms/microbiology , Helicobacter pylori , Helicobacter Infections/pathology , Precancerous Conditions/microbiology , Atrophy/microbiology , Stomach Neoplasms/pathology , Biopsy , Chronic Disease , Prevalence , Retrospective Studies , Risk Factors , Gastroscopy , Metaplasia/microbiology , Middle Aged
8.
Int J Mol Sci ; 20(8)2019 Apr 18.
Article in English | MEDLINE | ID: mdl-31003453

ABSTRACT

BACKGROUND: Helicobacter pylori (H. pylori) eradication therapy may improve gastric atrophy and intestinal metaplasia, but the results of previous studies have not always been consistent. The aim of this study was to compare the histological changes of intestinal metaplasia and gastric atrophy among the use of acid-suppressing drugs after H. pylori eradication. METHODS: A cohort of 242 patients who underwent successful eradication therapy for H. pylori gastritis and surveillance endoscopy examination from 1996 to 2015 was analyzed. Changes in the histological scores of intestinal metaplasia and atrophy according to drug use (proton-pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), and non-acid suppressant use) were evaluated in biopsies of the antrum and corpus using a generalized linear mixed model in all patients. RESULTS: The mean follow-up period and number of biopsies were 5.48 ± 4.69 years and 2.62 ± 1.67 times, respectively. Improvement in the atrophy scores of both the antrum (p = 0.042) and corpus (p = 0.020) were significantly superior in patients with non-acid suppressant drug use compared with those of PPI and H2RA use. Metaplasia scores in both the antrum and corpus did not improve in all groups, and no significant differences were observed among groups in the antrum (p = 0.271) and corpus (p = 0.077). CONCLUSIONS: Prolonged acid suppression by PPIs or H2RAs may limit the recovery of gastric atrophy following H. pylori eradication.


Subject(s)
Atrophy/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Proton Pump Inhibitors/administration & dosage , Adult , Aged , Aged, 80 and over , Atrophy/microbiology , Atrophy/physiopathology , Atrophy/prevention & control , Endoscopy , Female , Gastric Acid/metabolism , Gastric Mucosa/drug effects , Gastric Mucosa/microbiology , Gastric Mucosa/physiopathology , Gastritis/drug therapy , Gastritis/microbiology , Gastritis/physiopathology , Helicobacter Infections/microbiology , Helicobacter Infections/physiopathology , Helicobacter pylori/metabolism , Helicobacter pylori/pathogenicity , Humans , Intestines/drug effects , Intestines/microbiology , Intestines/physiopathology , Male , Metaplasia/drug therapy , Metaplasia/microbiology , Metaplasia/physiopathology , Middle Aged
9.
Helicobacter ; 24(3): e12579, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30920087

ABSTRACT

BACKGROUND: The aim of this study was to investigate the trends of atrophy and intestinal metaplasia (IM) in 2002 subjects without significant gastroduodenal diseases. MATERIALS AND METHODS: A total of 2002 subjects were prospectively enrolled and divided into three periods (2003-2007, 2008-2012, and 2013-2018). Trends of H pylori and atrophy/IM scored by Updated Sydney System were analyzed according to sex, and multivariate logistic analysis was performed for the risk factors for atrophy/IM. RESULTS: H pylori-negative and H pylori-positive subjects were 1220 (61.0%) and 782 (38.0%), respectively. H pylori positivity decreased from 149/303 (49.2%), 207/515 (40.2%) and 426/1184 (36.0%), in the three periods, respectively (P < 0.001). The prevalence of atrophy (P < 0.001) and IM in the corpus (P < 0.001) significantly decreased over 15 years in females, but not in males. The mean grade of atrophy and IM was higher in males (0.36 and 0.51) than in females (0.28 and 0.41) in the corpus (P = 0.027) and in the antrum (P = 0.006), respectively. Similarly, the mean grade of IM in males (0.34) was higher in females (0.19; P < 0.001) in the corpus. Multivariate analysis showed that old age, study period, and H pylori were statistically significant in atrophy of antrum and corpus, and IM in the corpus. In cases of IM of antrum, old age, H pylori, and smoking were statistically significant. CONCLUSION: A significant decrease in atrophy and IM in the corpus in females over 15 years suggests sex- or gender-specific characteristics.


Subject(s)
Atrophy/epidemiology , Helicobacter Infections/epidemiology , Helicobacter pylori/isolation & purification , Metaplasia/epidemiology , Adult , Aged , Atrophy/microbiology , Endoscopy, Digestive System , Female , Helicobacter Infections/microbiology , Humans , Intestines/microbiology , Male , Metaplasia/microbiology , Middle Aged , Prevalence , Prospective Studies , Republic of Korea/epidemiology , Risk Factors , Sex Factors
10.
Digestion ; 100(4): 277-285, 2019.
Article in English | MEDLINE | ID: mdl-30630185

ABSTRACT

BACKGROUND/AIM: Helicobacter pylori (HP) eradication therapy was first recommended as pharmacotherapy for functional dyspepsia (FD). However, the mechanism and effect of eradication on FD symptom improvement have not been fully investigated. This study aimed to investigate the pathology of patients with HP-associated FD, and predictive factors for HP-associated FD. METHODS: Ninety-seven patients with chronic gastritis caused by HP infection were divided into the group with FD symptoms and the group -without FD symptoms. Patient backgrounds, QOL, gastric mucosal atrophy severity, and serum pepsinogen (PG) value were compared between the 2 groups. Twelve months after eradication, those factors were evaluated between HP-associated FD and HP-non-associated FD, and predictive factors of HP-associated FD were analyzed. RESULTS: The FD-positive group existed in 45 (46.3%) out of 97 patients. Twelve months after eradication, there were 34 patients (75.6%) in the HP-associated FD. The mean PG I value in the HP-associated FD was significantly lower than that in the HP-non-associated FD, while the PG II values in the HP-associated FD tended to be lower than those in the HP-non-associated FD. QOL in the HP-associated FD significantly improved after HP eradication. On multivariate logistic regression analysis, it was found that PG II value was a significant predictive factor for FD symptom improvement in the HP-associated FD. CONCLUSION: HP eradication is an effective initial therapy for FD. PG II value is considered a predictive factor for FD symptom improvement through HP eradication.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Dyspepsia/blood , Dyspepsia/epidemiology , Helicobacter Infections/drug therapy , Helicobacter pylori/pathogenicity , Adult , Aged , Atrophy/blood , Atrophy/microbiology , Atrophy/pathology , Dyspepsia/microbiology , Dyspepsia/prevention & control , Female , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Helicobacter Infections/blood , Helicobacter Infections/complications , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Humans , Japan/epidemiology , Male , Middle Aged , Pepsinogen C/blood , Prospective Studies , Risk Assessment , Risk Factors
11.
World J Gastroenterol ; 24(35): 4061-4068, 2018 Sep 21.
Article in English | MEDLINE | ID: mdl-30254410

ABSTRACT

AIM: To clarify the role of serum anti-Helicobacter pylori (H. pylori) antibody titers in gastric cancer. METHODS: In this cross-sectional study, the effect of patients' baseline characteristics and endoscopic findings on their serum antibody titers were assessed. We evaluated consecutive patients who underwent esophagogastroduodenoscopy and their first evaluation for H. pylori infection using a serum antibody test. We excluded patients with a history of eradication therapy. The participants were divided into four groups according to their E-plate serum antibody titer. Patients with serum antibody titers < 3, 3-9.9, 10-49.9, and ≥ 50 U/mL were classified into groups A, B, C, and D, respectively. RESULTS: In total, 874 participants were analyzed with 70%, 16%, 8.7%, and 5.1% of them in the groups A, B, C, and D, respectively. Patients in group C were older than patients in groups A and B. Gastric open-type atrophy, intestinal metaplasia, enlarged folds, diffuse redness, and duodenal ulcers were associated with a high titer. Regular arrangements of collecting venules, fundic gland polyps, superficial gastritis, and gastroesophageal reflux disease were related to a low titer. Multivariate analysis revealed that nodularity (P = 0.0094), atrophy (P = 0.0076), and age 40-59 years (vs age ≥ 60 years, P = 0.0090) were correlated with a high serum antibody titer in H. pylori-infected patients. Intestinal metaplasia and atrophy were related to age ≥ 60 years in group C and D. CONCLUSION: Serum antibody titer changes with age, reflects gastric mucosal inflammation, and is useful in predicting the risk of gastric cancer.


Subject(s)
Antibodies/blood , Gastric Mucosa/pathology , Helicobacter Infections/blood , Helicobacter pylori/immunology , Intestinal Mucosa/pathology , Adult , Age Factors , Aged , Atrophy/blood , Atrophy/diagnostic imaging , Atrophy/immunology , Atrophy/microbiology , Cross-Sectional Studies , Endoscopy, Digestive System , Female , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/microbiology , Helicobacter Infections/immunology , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Helicobacter pylori/isolation & purification , Humans , Intestinal Mucosa/diagnostic imaging , Intestinal Mucosa/microbiology , Male , Metaplasia/blood , Metaplasia/diagnostic imaging , Metaplasia/immunology , Metaplasia/microbiology , Middle Aged , Retrospective Studies , Risk Factors , Serologic Tests
12.
World J Gastroenterol ; 24(20): 2163-2172, 2018 May 28.
Article in English | MEDLINE | ID: mdl-29853734

ABSTRACT

Helicobacter pylori (H. pylori) eradication can reduce gastric cancer. However, gastric cancer still develops after eradication, and cases who received eradication therapy are increasing. In this study, we have reviewed the characteristics and predictors of primary gastric cancer developing after H. pylori eradication. In terms of the characteristics, endoscopic, histologic, and molecular characteristics are reported. Endoscopically, gastric cancer after eradication is often depressed-type and shows a gastritis-like appearance, which sometimes makes the diagnosis difficult. Histologically, most gastric cancer after eradication is intestinal type, and non-neoplastic epithelium, also called epithelium with low-grade atypia, is frequently seen over the tumor, which is presumably the cause of the endoscopic gastritis-like appearance. As for molecular characteristics, some markers, such as Ki67, MUC2, and Wnt5a expression, are lower in cancer from patients in whom H. pylori has been eradicated. In terms of predictors, several Japanese studies have reported that severe endoscopic atrophy at eradication is a risk factor for gastric cancer development. Histologic intestinal metaplasia, especially in the corpus, and long-term use of proton pump inhibitors, are also reported as risk factors for gastric cancer after H. pylori eradication. These studies on the characteristics and predictors of gastric cancer development will become the cornerstone for establishing a novel surveillance program based on the gastric cancer risk stratification specific to H. pylori-eradicated patients.


Subject(s)
Atrophy/diagnostic imaging , Gastric Mucosa/pathology , Helicobacter Infections/drug therapy , Metaplasia/pathology , Stomach Neoplasms/epidemiology , Anti-Bacterial Agents/therapeutic use , Atrophy/microbiology , Atrophy/pathology , Biomarkers, Tumor/analysis , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/microbiology , Gastroscopy , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Humans , Metaplasia/diagnostic imaging , Metaplasia/microbiology , Proton Pump Inhibitors/therapeutic use , Risk Assessment , Risk Factors , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathology
13.
World J Gastroenterol ; 24(15): 1591-1600, 2018 Apr 21.
Article in English | MEDLINE | ID: mdl-29686466

ABSTRACT

Chronic kidney disease (CKD) patients receiving hemodialysis (HD) often develop gastrointestinal abnormalities over their long treatment period. In general, prognosis in such patients is poor due to the development of protein-energy wasting (PEW). Therefore, it is important to clarify the etiology of PEW and to establish better strategies to deal with this condition. Chronic Helicobacter pylori (H. pylori) infection in the gastric mucosa has a close association with not only the development of peptic ulcer disease and gastric cancer, but is also associated with abnormal plasma and gastric mucosal ghrelin levels that are seen in malnutrition. It is unclear whether H. pylori infection of the gastric mucosa is directly associated with prognosis in HD patients by affecting ghrelin levels. Recent studies show that the prevalence of H. pylori infection in HD patients is significantly lower than in subjects with normal renal function. In the natural history of H. pylori infection in HD patients, the prevalence of infection decreases as the length of time on HD increases. The severity of gastric mucosal atrophy has been suggested as the major determinant of ghrelin levels in these patients, and eradication therapy of H. pylori improves nutritional status by increasing serum cholinesterase and cholesterol levels, especially in patients with mild-to-moderate gastric mucosal atrophy. Prompt H. pylori eradication to inhibit the progress of gastric atrophy may be required to prevent this decrease in ghrelin levels and subsequent PEW and improve the prognosis of HD patients by improving their nutritional status.


Subject(s)
Helicobacter Infections/metabolism , Nutritional Status , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/therapy , Wasting Syndrome/metabolism , Anti-Bacterial Agents/therapeutic use , Atrophy/metabolism , Atrophy/microbiology , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Ghrelin/blood , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/isolation & purification , Humans , Prevalence , Prognosis , Renal Insufficiency, Chronic/metabolism , Time Factors , Wasting Syndrome/blood , Wasting Syndrome/microbiology , Wasting Syndrome/prevention & control
14.
Gastric Cancer ; 21(5): 745-755, 2018 09.
Article in English | MEDLINE | ID: mdl-29427040

ABSTRACT

BACKGROUND: The risk stratification of healthy individuals after Helicobacter pylori eradication is an urgent issue. The assessment of aberrant DNA methylation accumulated in gastric tissues with normal appearance, which can reflect overall epigenomic damage, is a promising strategy. We aimed to establish novel epigenetic cancer risk markers for H. pylori-eradicated individuals. METHODS: Gastric mucosa was collected from eight healthy volunteers without H. pylori infection (G1), 75 healthy individuals with gastric atrophy (G2), and 94 gastric cancer patients (G3) after H. pylori eradication. Genome-wide analysis was conducted using Infinium 450 K and differentially methylated probes were screened using large difference and iEVORA-based methods. Bisulfite pyrosequencing was used for validation. RESULTS: Screening, using 8 G1, 12 G2, and 12 G3 samples, isolated 57 candidates unmethylated in G1 and differentially methylated in G3 compared with G2. Validation for nine candidate markers (FLT3, LINC00643, RPRM, JAM2, ELMO1, BHLHE22, RIMS1, GUSBP5, and ZNF3) in 63 G2 and 82 G3 samples showed that all of them had significantly higher methylation levels in G3 than in G2 (P < 0.0001). Their methylation levels were highly correlated, which indicated that they reflect overall epigenomic damage. The candidates had sufficient performance (AUC: 0.70-0. 80) and high odds ratios (5.43-23.41), some of which were superior to a previous marker, miR-124a-3. The methylation levels of our novel markers were not associated with gastric atrophy, gender, or age. CONCLUSIONS: Novel epigenetic markers for gastric cancer risk optimized for H. pylori-eradicated individuals were established.


Subject(s)
Biomarkers, Tumor/genetics , Epigenesis, Genetic , Helicobacter Infections/complications , Stomach Neoplasms/genetics , Adult , Age Factors , Aged , Atrophy/microbiology , DNA Methylation , Female , Gastric Mucosa/pathology , Gene Expression Regulation, Neoplastic , Genome-Wide Association Study , Helicobacter Infections/therapy , Helicobacter pylori/pathogenicity , Humans , Male , Reproducibility of Results , Stomach Neoplasms/microbiology
15.
Dig Dis Sci ; 62(6): 1561-1570, 2017 06.
Article in English | MEDLINE | ID: mdl-28281170

ABSTRACT

BACKGROUND AND AIM: Upper gastrointestinal (UGI) symptoms are common; however, the role of Helicobacter pylori and gastric corpus atrophy in the generation of these symptoms is controversial. The aim of this study was to determine the risk factors for UGI symptoms in adults in an endemic area of H. pylori infection. METHODS: Korean adults who completed questionnaires on the day of serum anti-H. pylori IgG and pepsinogen (PG) assays before UGI endoscopy were included. Gastric corpus atrophy was based on the criteria of a serum PG I/II ratio <3.0 and a PG I <70 ng/ml. RESULTS: Of the 2275 included subjects, 723 (31.8%) had at least one UGI symptom. A total of 374 (16.4%) subjects had multiple symptoms without significant correlations between the symptoms (λ < 0.2). The H. pylori serology assay was positive in 1382 (60.7%) subjects, and gastric corpus atrophy was present in 291 (12.8%). Neither H. pylori seropositivity (p = 0.077) nor gastric corpus atrophy (p = 0.138) was related to the presence of UGI symptoms. Female gender and smoking were independent risk factors for heartburn and upper abdominal pain (all p < 0.001). Furthermore, female gender was the only independent risk factor for multiple UGI symptoms (p < 0.001), globus sensation (p < 0.001), early satiety (p < 0.001), epigastric soreness (p = 0.001), and chest discomfort (p = 0.003). CONCLUSIONS: In an H. pylori seroprevalent population, female gender is the most common risk factor followed by smoking for UGI symptom generation. Neither H. pylori seropositivity nor gastric corpus atrophy is an independent risk factor for UGI symptom generation.


Subject(s)
Gastric Mucosa/pathology , Heartburn/epidemiology , Helicobacter Infections/blood , Helicobacter Infections/complications , Helicobacter pylori , Immunoglobulin G/blood , Abdominal Pain/epidemiology , Adult , Alcoholism/epidemiology , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Atrophy/microbiology , Cross-Sectional Studies , Deglutition Disorders/epidemiology , Endoscopy, Gastrointestinal , Female , Helicobacter pylori/immunology , Humans , Male , Middle Aged , Nausea/epidemiology , Pepsinogen A/blood , Pepsinogen C/blood , Prevalence , Republic of Korea/epidemiology , Risk Factors , Sex Factors , Smoking/epidemiology , Stomach , Surveys and Questionnaires , Symptom Assessment , Vomiting/epidemiology
16.
Int J Dermatol ; 56(6): 664-668, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28321841

ABSTRACT

BACKGROUND: Histoid leprosy is a rare variant of lepromatous leprosy characterized by varied morphological and histopathological appearance while having a high bacillary load. These factors contribute to an ominous threat to the elimination status of leprosy, whereby these patients may act as a reservoir of infection. OBJECTIVE: To identify the clinicopathological characteristics of histoid leprosy in Chitwan, Nepal. METHODS: A retrospective hospital-based study spanning a period of 6 years was carried out at our department. All cases clinically and histopathologically suggestive of histoid leprosy were included in our study, and all relevant data were recorded and analyzed as per standard protocol. RESULTS: Histoid leprosy comprised 2.9% of all leprosy cases. Mean age of 39.45 years and male:female ratio of 1.75:1 were seen. Previous history of leprosy was obtained in 72.7%, and de novo development of histoid leprosy took place in 27.3%. Papules were the most common lesion seen, and upper limbs were the most frequent site of involvement, and the ulnar nerve was enlarged in most cases. Mean bacillary index was 5.39. Histopathology showed epidermal atrophy, positive Fite-Faraco stain for lepra bacilli, spindle-shaped histiocytes arranged in various patterns, and a well-circumscribed area of cells in the dermis in all cases. Grenz zone and pseudocapsule were seen in the majority of patients. All cases responded well to multibacillary multidrug therapy (MB-MDT) of 2 years. CONCLUSION: A high index of suspicion is essential for diagnosing histoid leprosy, both clinically and histopathologically.


Subject(s)
Epidermis/pathology , Leprosy, Lepromatous/pathology , Adult , Aged , Atrophy/microbiology , Back , Bacterial Load , Drug Therapy, Combination , Facial Dermatoses/microbiology , Female , Histiocytes/pathology , Humans , Leprostatic Agents/therapeutic use , Leprosy, Lepromatous/diagnosis , Leprosy, Lepromatous/drug therapy , Lower Extremity , Male , Middle Aged , Nepal , Recurrence , Retrospective Studies , Ulnar Nerve/pathology , Upper Extremity , Young Adult
17.
Am J Nephrol ; 44(3): 224-33, 2016.
Article in English | MEDLINE | ID: mdl-27578611

ABSTRACT

BACKGROUND: Ghrelin, an orexigenic hormone, has multiple favorable functions including protein anabolism enhancement, anti-inflammatory actions, and cardiovascular protection. A low plasma ghrelin level is associated with increased mortality in patients treated with hemodialysis (HD). However, it is unclear whether the plasma ghrelin level in HD patients correlates with the severity of gastric mucosal atrophy and Helicobacter pylori status. METHODS: Seventy-eight maintenance HD patients and 51 non-dialysis patients with chronic kidney disease were evaluated for severity of gastric mucosal atrophy by gastroduodenoscopy and for H. pylori status using an anti-H. pylori-antibody and rapid urease test. Plasma acyl and des-acyl ghrelin levels were measured and their associations with relevant clinical parameters were investigated. RESULTS: Des-acyl ghrelin level in HD patients was significantly higher than that in patients with kidney function preserved. Although acyl and des-acyl ghrelin levels were similar between current H. pylori positive and negative HD patients, both levels decreased significantly with the progress of endoscopic gastric mucosal atrophy in HD patients. Serum pepsinogen (PG) I level and PG I/II ratio decreased significantly according to the severity of atrophy in HD patients and positively significantly correlated with both ghrelin levels. Multiple regression analysis showed significant positive correlations between acyl ghrelin and PG I levels (ß = 0.738, p < 0.001) and significant negative correlations between ghrelin and age, albumin, and creatinine levels. CONCLUSIONS: Gastric atrophy is the major determinant of ghrelin level in HD patients. Management practices, such as H. pylori eradication, before advanced atrophy may be required to prevent the decrease of ghrelin levels and improve the prognosis of HD patients.


Subject(s)
Gastric Mucosa/pathology , Ghrelin/blood , Helicobacter Infections/blood , Helicobacter pylori , Renal Insufficiency, Chronic/therapy , Age Factors , Aged , Aged, 80 and over , Atrophy/blood , Atrophy/diagnostic imaging , Atrophy/microbiology , Breath Tests , Creatinine/blood , Gastroscopy , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Humans , Middle Aged , Pepsinogen A/blood , Pepsinogen C/blood , Renal Dialysis , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/complications , Serum Albumin/metabolism , Severity of Illness Index
18.
Clin Dermatol ; 34(4): 487-94, 2016.
Article in English | MEDLINE | ID: mdl-27343964

ABSTRACT

Oral candidiasis (OC) is a common fungal disease encountered in dermatology, most commonly caused by an overgrowth of Candida albicans in the mouth. Although thrush is a well-recognized presentation of OC, it behooves clinicians to be aware of the many other presentations of this disease and how to accurately diagnose and manage these cases. The clinical presentations of OC can be broadly classified as white or erythematous candidiasis, with various subtypes in each category. The treatments include appropriate oral hygiene, topical agents, and systemic medications. This review focuses on the various clinical presentations of OC and treatment options.


Subject(s)
Antifungal Agents/therapeutic use , Candidiasis, Oral/drug therapy , Mouth Mucosa/pathology , Administration, Oral , Administration, Topical , Antifungal Agents/administration & dosage , Atrophy/microbiology , Candidiasis, Chronic Mucocutaneous/complications , Candidiasis, Chronic Mucocutaneous/diagnosis , Candidiasis, Oral/complications , Candidiasis, Oral/diagnosis , Cheilitis/microbiology , Erythema/microbiology , Glossitis/microbiology , Humans , Hyperplasia/microbiology
20.
BMC Gastroenterol ; 15: 95, 2015 Aug 04.
Article in English | MEDLINE | ID: mdl-26239636

ABSTRACT

BACKGROUND: The grade of gastric mucosa atrophy caused by Helicobacter pylori (H. pylori) infection is closely associated with the risk of gastric cancer, especially of the intestinal type. Interobserver and intraobserver agreement for endoscopic gastric mucosa atrophy in subjects with H. pylori-uninfected, currently infected and past infected was investigated. METHODS: Endoscopic images of 91 patients, 34 images per patient, were assessed. The assessors were 4 endoscopist groups: Japanese and Vietnamese experienced (≥7, ≤ 15 year experience with endoscopy) and Japanese and Vietnamese beginner (≤ 3 year experience) groups. Each group comprised 3 endoscopists. The grades of atrophy were classified as 3: none to mild (C-0 and C-1), moderate (C-2 and C-3), and severe (O-1, O-2, and O-3) using the Kimura-Takemoto Classification. After a period of 2 weeks, images of all patients were reevaluated by the investigators. Interobserver and intraobserver agreement was calculated by kappa statistics. RESULTS: The kappa values for the interobserver agreement in the groups of Japanese and Vietnamese experienced, and Japanese and Vietnamese beginner were 0.474, 0.408, 0.291, and 0.373, respectively. The kappa value of intraobsever agreement in the Japanese and Vietnamese experienced endoscoists ranged from 0.585 to 0.871. On the other hand, the value in the beginner endoscopists ranged wider than that in experienced endoscopists, from 0.264 to 0.866. CONCLUSIONS: Our results indicated that, although intraobserver agreement for gastric mucosa atrophy was good to excellent, interobserver agreement was moderate in experienced endoscopists. This suggests that better guidelines and firm criteria may be needed to properly diagnose and grade gastric atrophy.


Subject(s)
Gastric Mucosa/pathology , Helicobacter Infections/complications , Helicobacter pylori , Aged , Atrophy/microbiology , Atrophy/pathology , Clinical Competence , Female , Gastroscopy , Humans , Japan , Male , Middle Aged , Observer Variation , Severity of Illness Index , Vietnam
SELECTION OF CITATIONS
SEARCH DETAIL
...